池田 康博 (イケダ ヤスヒロ)

IKEDA Yasuhiro

写真a

所属

医学部 医学科 感覚運動医学講座眼科学分野

外部リンク

学位 【 表示 / 非表示

  • 博士(医学) ( 2003年3月   九州大学 )

研究分野 【 表示 / 非表示

  • ライフサイエンス / 眼科学

所属学協会 【 表示 / 非表示

  • 日本網膜硝子体学会

    2008年4月 - 現在

  • 日本緑内障学会

    2006年4月 - 現在

  • The Association for Research in Vision and Ophthalmology (ARVO)

    2000年10月 - 現在

  • 日本遺伝子細胞治療学会

    1999年4月 - 現在

  • 日本眼科学会

    1995年5月 - 現在

 

論文 【 表示 / 非表示

  • Effects of internal limiting membrane peeling on anatomical and functional outcomes in macula-off rhegmatogenous retinal detachment complicated by proliferative vitreoretinopathy: Japan-Retinal Detachment Registry 査読あり

    Obata S., Sawada O., Kakinoki M., Matsumoto R., Saishin Y., Ohji M., Yamamoto S., Baba T., Sato E., Kitahashi M., Tatsumi T., Miura G., Nizawa T., Sakamoto T., Yamakiri K., Yamashita T., Otsuka H., Sameshima S., Yoshinaga N., Sonoda S., Hirakata A., Koto T., Inoue M., Hirota K., Itoh Y., Orihara T., Emoto Y., Sano M., Takahashi H., Tokizawa R., Yamashita H., Nishitsuka K., Kaneko Y., Nishi K., Yoshida A., Ono S., Hirokawa H., Sogawa K., Omae T., Ishibazawa A., Kishi S., Akiyama H., Matsumoto H., Mukai R., Morimoto M., Nakazawa M., Suzuki Y., Kudo T., Adachi K., Ishida S., Noda K., Kase S., Mori S., Ando R., Saito M., Suzuki T., Takahashi K., Nagai Y., Nakauchi T., Yamada H., Kusaka S., Tsujioka D., Tsujikawa A., Suzuma K., Ishibashi T., Sonoda K.H., Ikeda Y., Kohno R., Ishikawa K., Kondo M., Kozawa M., Kitaoka T., Tsuiki E., Ogura Y., Yoshida M., Morita H., Kato A., Hirano Y., Sugitani K., Terasaki H., Iwase T., Ito Y., Ueno S., Kaneko H., Nonobe N., Kominami T., Azuma N., Yokoi T., Shimada H., Nakashizuka H., Hattori T., Shinojima A., Kitagawa Y., Shiraga F., Morizane Y., Kimura S., Ikeda T., Kida T., Sato T., Fukumoto M.

    Japanese Journal of Ophthalmology   67 ( 4 )   417 - 423   2023年7月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Japanese Journal of Ophthalmology  

    Purpose: To investigate the effects of internal limiting membrane (ILM) peeling on retinal attachment after a single surgery, and on postoperative visual acuity (VA) at 6 months, in eyes with macula-off rhegmatogenous retinal detachment (RRD) complicated by proliferative vitreoretinopathy (PVR). Study design: Nationwide, multicenter retrospective cohort study. Methods: The Japan-RD Registry database was used for analysis of patients who had undergone vitrectomy for macula-off RRD complicated by PVR. Multivariate analysis was performed to detect prognostic factors for retinal attachment after a single surgery and for VA at 6 months postoperatively. Retinal attachment after a single surgery or VA at 6 months postoperatively was the objective variable; ILM peeling, preoperative VA, PVR grade, age, and intraocular pressure were explanatory variables. Results: Eighty-nine eyes met the inclusion criteria; ILM peeling was performed in 25 eyes (28%). Preoperative VA was significantly associated with retinal attachment, but ILM peeling did not (odds ratios = 2.1 and 1.3, respectively; p = 0.009 and 0.67, respectively). Poor preoperative VA and younger patient age were significantly associated with poor postoperative VA, but ILM peeling was not (β-values = 0.37, −0.008, and 0.15, respectively; p < 0.001, p = 0.02, and p = 0.15, respectively. Conclusions: Preoperative VA was a risk factor associated with retinal attachment. Preoperative VA and patient age were risk factors associated with postoperative poor VA. In eyes with macula-off RRD complicated by PVR, ILM peeling did not have a clear beneficial effect on anatomical and functional outcomes, suggesting that it may be unnecessary for eyes with this condition.

    DOI: 10.1007/s10384-023-01000-y

    Scopus

  • Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial 査読あり

    Shimura M., Kitano S., Ogata N., Mitamura Y., Oh H., Ochi H., Ohsawa S., Hirakata A., Bolz M., Findl O., Pollreisz A., Weger M., Daskalov V., Misheva A., Petkova I., Guneva D.T., Vassileva P., Cornut P.L., Korobelnik J.F., Lebreton O., Tadayoni R., Eter N., Feltgen N., Framme C., Lorenz K., Spital G., Bator G., Seres A., Szalczer L., Toth-Molnar E., Vajas A., Varsanyi B., Goldstein M., Levy J., Morori-Katz H., Rosenblatt I., Yoreh B., Bandello F., Cagini C., Mastropasqua L., Nicolo M., Parravano M.C., Viola F., Fukutomi A., Hayashi K., Hirakata A., Honda S., Ikeda Y., Ito Y., Kawasaki T., Kimura K., Kishino G., Kitano S., Maeno T., Murakami T., Noda K., Obana A., Oh H., Sawada O., Shimouchi A., Sugimoto M., Sugita I., Takagi H., Takayama K., Tanabe T., Yasukawa T., Yoshida S., Garcia R., Rechy D.L., Canton V.M., Estudillo J.R., Barraza K., Fernandez C., Guzman M., Lujan S., Gawecki M., Herba E., Michalska-Malecka K., Muzyka-Wozniak M., Nester-Ostrowska K., Oleksy P., Wowra B., Wylęgała E., Budzinskaya M., Kulikov A., Morugova T., Hurcikova M., Kacerík M., Lipkova B., Abengoechea S., Civera A.A., Amat P., Cabrera F., Cava C., Garcia-Layana A., Ulla F.G., Moreno J.M.R.

    Japanese Journal of Ophthalmology   67 ( 3 )   264 - 279   2023年5月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Japanese Journal of Ophthalmology  

    Purpose: To evaluate efficacy, durability, and safety of faricimab in Japanese patients with diabetic macular edema (DME). Study design: Subgroup analysis of 2 global, multicenter, randomized, double-masked, active-comparator–controlled, phase 3 trials (YOSEMITE, NCT03622580; RHINE, NCT03622593). Methods: Patients with DME were randomized 1:1:1 to intravitreal faricimab 6.0 mg every 8 weeks (Q8W), faricimab 6.0 mg per personalized treatment interval (PTI), or aflibercept 2.0 mg Q8W through week 100. Primary endpoint was best-corrected visual acuity (BCVA) change from baseline at 1 year, averaged over weeks 48, 52, and 56. This is the first time 1-year outcomes between Japanese patients (only enrolled into YOSEMITE) and the pooled YOSEMITE/RHINE cohort (N = 1891) have been compared. Results: The YOSEMITE Japan subgroup included 60 patients randomized to faricimab Q8W (n = 21), faricimab PTI (n = 19), or aflibercept Q8W (n = 20). Consistent with global results, the adjusted mean (95.04% confidence interval) BCVA change at 1 year in the Japan subgroup was comparable with faricimab Q8W (+11.1 [7.6–14.6] letters), faricimab PTI (+8.1 [4.4–11.7] letters), and aflibercept Q8W (+6.9 [3.3–10.5] letters). At week 52, 13 (72%) patients in the faricimab PTI arm achieved ≥ Q12W dosing, including 7 (39%) patients receiving Q16W dosing. Anatomic improvements with faricimab were generally consistent between the Japan subgroup and pooled YOSEMITE/RHINE cohort. Faricimab was well tolerated; no new or unexpected safety signals were identified. Conclusion: Consistent with global results, faricimab up to Q16W offered durable vision gains and improved anatomic and disease-specific outcomes among Japanese patients with DME.

    DOI: 10.1007/s10384-023-00979-8

    Scopus

  • 特集 日本の眼の難病-何がどこまでわかってきたのか? 網膜色素変性の疾患レジストリ 査読あり

    池田 康博

    臨床眼科   77 ( 1 )   37 - 40   2023年1月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:株式会社医学書院  

    DOI: 10.11477/mf.1410214680

    CiNii Research

  • Drinking hydrogen water improves photoreceptor structure and function in retinal degeneration 6 mice 査読あり

    Igarashi T., Ohsawa I., Kobayashi M., Miyazaki K., Igarashi T., Kameya S., Shiozawa A.L., Ikeda Y., Miyagawa Y., Sakai M., Okada T., Sakane I., Takahashi H.

    Scientific Reports   12 ( 1 )   13610   2022年12月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Scientific Reports  

    Retinitis pigmentosa (RP) is a genetically heterogeneous group of inherited retinal disorders involving the progressive dysfunction of photoreceptors and the retinal pigment epithelium, for which there is currently no treatment. The rd6 mouse is a natural model of autosomal recessive retinal degeneration. Given the known contributions of oxidative stress caused by reactive oxygen species (ROS) and selective inhibition of potent ROS peroxynitrite and OH·by H2 gas we have previously demonstrated, we hypothesized that ingestion of H2 water may delay the progression of photoreceptor death in rd6 mice. H2 mice showed significantly higher retinal thickness as compared to controls on optical coherence tomography. Histopathological and morphometric analyses revealed higher thickness of the outer nuclear layer for H2 mice than controls, as well as higher counts of opsin red/green-positive cells. RNA sequencing (RNA-seq) analysis of differentially expressed genes in the H2 group versus control group revealed 1996 genes with significantly different expressions. Gene and pathway ontology analysis showed substantial upregulation of genes responsible for phototransduction in H2 mice. Our results show that drinking water high in H2 (1.2–1.6 ppm) had neuroprotective effects and inhibited photoreceptor death in mice, and suggest the potential of H2 for the treatment of RP.

    DOI: 10.1038/s41598-022-17903-8

    Scopus

    PubMed

  • Incidence of Leber hereditary optic neuropathy in 2019 in Japan: a second nationwide questionnaire survey. 査読あり

    Takano F, Ueda K, Godefrooij DA, Yamagami A, Ishikawa H, Chuman H, Ishikawa H, Ikeda Y, Sakamoto T, Nakamura M

    Orphanet journal of rare diseases   17 ( 1 )   319   2022年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Orphanet Journal of Rare Diseases  

    Background: Leber hereditary optic neuropathy (LHON) is an acute or subacute optic neuropathy that mainly affects young males. The first nationwide epidemiological survey of LHON was conducted in 2014 in Japan, and LHON was officially designated as a rare intractable disease by the Japanese government in 2015. We conducted a second survey of the annual incidence of LHON in 2019, and estimated the total number of patients with LHON in Japan. Results: A questionnaire was sent to 997 facilities accredited by the Japanese Ophthalmological Society and/or affiliated with the councilors of the Japanese Neuro-Ophthalmology Society. Responses were received from 791 facilities, with a response rate of 79%. Fifty-five newly diagnosed cases (49 males and 6 females) of LHON were reported from 35 institutions in 2019, with a median age of 28.5 for males and 49.5 years for females. The total number of newly diagnosed cases was calculated as 69 (62 were males and 7 were females, 95% confidence interval 55–83), and the total number of patients was estimated to be 2491 (95% confidence interval: 1996–2986), suggesting a prevalence of LHON in Japan of 1:50,000. Conclusion: The incidence of LHON in 2019 was lower than the estimate in 2014, whereas its prevalence may be similar to that reported in other countries. The accurate estimation of the incidence and prevalence of patients with LHON requires prospective registration.

    DOI: 10.1186/s13023-022-02478-4

    Scopus

    PubMed

全件表示 >>

書籍等出版物 【 表示 / 非表示

  • 眼科診療ビジュアルラーニング5 「網膜, 硝子体」

    池田 康博( 担当: 分担執筆)

    中山書店  2020年9月 

     詳細を見る

    記述言語:日本語

  • 眼疾患アトラスシリーズ2 「後眼部アトラス」

    池田 康博( 担当: 分担執筆)

    総合医学社  2019年10月 

     詳細を見る

    記述言語:日本語

  • 眼疾患アトラスシリーズ2 「後眼部アトラス」

    池田 康博( 担当: 分担執筆)

    総合医学社  2019年10月 

     詳細を見る

    記述言語:日本語

MISC 【 表示 / 非表示

  • 【眼科領域の最新医療・プレシジョンメディシン】網膜色素変性の遺伝子治療

    池田康博

    Precision Medicine   2020年2月

     詳細を見る

    記述言語:日本語   掲載種別:記事・総説・解説・論説等(学術雑誌)  

  • 【眼科の先進的医療Up to Date】遺伝性網膜変性疾患の遺伝子治療

    池田康博

    あたらしい眼科   2019年11月

     詳細を見る

    記述言語:日本語   掲載種別:記事・総説・解説・論説等(学術雑誌)  

  • 機器・薬剤紹介 HOYA暗所視支援眼鏡MW-10 HiKARI

    池田康博

    眼科   2019年9月

     詳細を見る

    記述言語:日本語   掲載種別:記事・総説・解説・論説等(学術雑誌)  

  • 【知っておきたい稀な網膜・硝子体ジストロフィ】錐体杆体ジストロフィ

    吉田倫子、池田康博

    OCULISTA   2019年6月

     詳細を見る

    記述言語:日本語   掲載種別:記事・総説・解説・論説等(学術雑誌)  

  • 【眼科医の手引】 暗所視支援眼鏡

    池田康博

    日本の眼科   2019年3月

     詳細を見る

    記述言語:日本語   掲載種別:記事・総説・解説・論説等(学術雑誌)  

全件表示 >>

科研費(文科省・学振・厚労省)獲得実績 【 表示 / 非表示

  • 網膜色素変性を自然発症するカニクイザルの繁殖と治療法開発への応用

    研究課題/領域番号:22K09769  2022年04月 - 2025年03月

    独立行政法人日本学術振興会  科学研究費補助金  基盤研究(C)

     詳細を見る

    担当区分:研究代表者 

  • 短後毛様動脈虚血による正常眼圧緑内障モデルの作成とアドレノメジュリン効果の検討

    研究課題/領域番号:22K09770  2022年04月 - 2025年03月

    独立行政法人日本学術振興会  科学研究費補助金  基盤研究(C)

    中馬 秀樹、

     詳細を見る

    担当区分:研究分担者 

 

授業 【 表示 / 非表示

  • 生命と病気